Massive transfusion in The Netherlands

Rijnhout, Tim W.H.; Noorman, Femke; Bek, Annemarije; Zoodsma, Margreet; Hoencamp, Rigo

doi:10.1136/emermed-2019-208665

Cited by 6 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43,44 Based on the data of this study, WB has equal fibrinogen content as a unit of apheresis plasma despite its higher plasma volume, which is due to the higher citrate dilution of WB compared to apheresis plasma. 45 Furthermore universal donor type O required for early transfusion of WB, has lower factor VIII activities compared to other blood groups. 46 In clinical practice these small differences in coagulation factor activity will probably have minimal impact on the clinical outcome of patients with major hemorrhage.…”

Section: Discussionmentioning

confidence: 99%

Prolonged (post‐thaw) shelf life of −80°C frozen AB apheresis plasma

Rijnhout

Noorman²,

Kort³

et al. 2020

Transfusion

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Early plasma transfusion is important in the treatment of patients with major hemorrhage. Prolonged shelf life of AB type frozen −80°C and coldstored (4°C) deep frozen plasma (DFP) will improve strategic stock management, minimize need for resupply, and make pre-hospital implementation more feasible. METHODS AND MATERIALS: Plasma products type AB of different age and origin (−30°C Fresh Frozen [(FFP], −80°C DFP [short (AE1 year) and long (AE7 year)] stored) were thawed (Day 0), stored at 4°C, and sampled on Days 7 and 14. Additionally, samples of plasma containing blood products (Octaplas LG ® , whole blood and platelets) were compared for coagulation factor activity, phospholipid clotting time (PPL), and kaolin TEG during 4°C or 22°C storage. RESULTS: Coagulation profiles of FFP, short-and longstored −80°C DFP were not significantly different after thaw. Cold storage did not affect fibrinogen, Protein C, and Antithrombin III activities whereas factor V, VII, VIII, and Protein S decreased in all blood products. After 14 days DFP still meets the guidelines for clinical use, except for Protein S (0.4 IU/mL). With exception of Octaplas LG ® , phospholipid activity and TEG coagulation were similar between plasma containing blood components during storage. CONCLUSION: AB DFP quality was unaffected by almost 7 years of frozen storage. Quality of thawed 14day stored AB DFP met, with exception of Protein S, all minimal guidelines which implies that its quality is sufficient for use in the (pre)-hospital (military) environment for treatment of major hemorrhage.

show abstract

Section: Discussionmentioning

confidence: 99%

Prolonged (post‐thaw) shelf life of −80°C frozen AB apheresis plasma

Rijnhout

Noorman²,

Kort³

et al. 2020

Transfusion

Self Cite

View full text Add to dashboard Cite

show abstract

“…With approximately 40 0-50 0 admitted severely injured trauma patients (with injury severity score of ≥ 16) and 160 MTP activations, annually this level 1 trauma centre has the highest polytrauma patient load in the Netherlands. [10] A total of 113 surveys were sent to potential local respondents situated in the departments of surgery ( n = 33), anaesthesiology ( n = 50) and the emergency department (ED) ( n = 30).…”

Section: Local Survey: Within All Departments Of One Level 1 Trauma Centrementioning

confidence: 99%

“…[ 8 , 9 ] Despite availability of a national guideline in the Netherlands, MTP content in all level 1 trauma centres is varying and whether transfusion practice is concordant with local MTP or is driven by expert opinion or other guidelines is currently not known. [10] Albeit the evidence that early and correct MTP use results in improved coagulation, survival benefit and cost reduction, it is expected that actual knowledge regarding the correct MTP strategy is low. [ 5 , 11-14 ] The aim is to determine MTP knowledge and massive transfusion strategy for trauma patients.…”

Section: Introductionmentioning

confidence: 99%

Massive transfusion protocols in the Netherlands. Consensus or confusion?

Rijnhout

Noorman

Waes

et al. 2022

Injury

Self Cite

View full text Add to dashboard Cite

“…( 8) 18) It should however be noted that even between trauma centres there is a significant variation in practice and the regimen used. (33) Looking at adverse events between groups, one study (n= 354) reported a higher incidence of AKI in the WB group compared with component therapy. (30) Another study (n=369) found a higher incidence of ARDS in the FWB group compared to aPLT group.…”

Section: Sub-analysis Of Patients With Tbimentioning

confidence: 99%

Whole blood transfusion versus component therapy in adult trauma patients with acute major haemorrhage

et al. 2020

View full text Add to dashboard Cite

ObjectiveIn the era of damage control resuscitation of trauma patients with acute major haemorrhage, transfusion practice has evolved to blood component (component therapy) administered in a ratio that closely approximates whole blood (WB). However, there is a paucity of evidence supporting the optimal transfusion strategy in these patients. The primary objective was therefore to establish if there is an improvement in survival at 30 days with the use of WB transfusion compared with blood component therapy in adult trauma patients with acute major haemorrhage.MethodologyA systematic literature search was performed on 15 December 2019 to identify studies comparing WB transfusion with component therapy in adult trauma patients and mortality at 30 days. Studies which did not report mortality were excluded. Methodological quality of included studies was interpreted using the Cochrane risk of bias tool, and rated using the Grading of Recommendations Assessment, Development and Evaluation approach.ResultsSearch of the databases identified 1885 records, and six studies met the inclusion criteria involving 3255 patients. Of the three studies reporting 30-day mortality (one randomised controlled trial (moderate evidence) and two retrospective (low and very low evidence, respectively)), only one study demonstrated a statistically significant difference between WB and component therapy, and two found no statistical difference. Two retrospective studies reporting in-hospital mortality found no statistical difference in unadjusted mortality, but both reported statistically significant logistic regression analyses demonstrating that those with a WB transfusion strategy were less likely to die.ConclusionRecognising the limitations of this systematic review relating to the poor-quality evidence and limited number of included trials, it does not provide evidence to support or reject use of WB transfusion compared with component therapy for adult trauma patients with acute major haemorrhage.PROSPERO registration numberCRD42019131406.

show abstract

Massive transfusion in The Netherlands

Cited by 6 publications

References 18 publications

Prolonged (post‐thaw) shelf life of −80°C frozen AB apheresis plasma

Prolonged (post‐thaw) shelf life of −80°C frozen AB apheresis plasma

Massive transfusion protocols in the Netherlands. Consensus or confusion?

Whole blood transfusion versus component therapy in adult trauma patients with acute major haemorrhage

Contact Info

Product

Resources

About